The companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacle platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.

Following reports of destroyed and discarded data, the U.S. regulator issued a warning letter to India’s Intas Pharmaceuticals regarding violations of current good manufacturing practice.

Siemens Healthineers lowered its profit margin outlook for Varian due to “temporary challenges in outbound logistics” at its U.S. maker of devices and software for treating cancer to 14-15% from a previous 16-18%.

The company posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.

The license and option deal, for an undisclosed amount, seeks to develop potentially first-in-class antibody-drug conjugate candidates against different oncology targets.

Lawyers for a California man who says he developed a rare cancer from exposure to asbestos in Johnson & Johnson’s talc-based baby powder on Monday urged a jury to order the company to pay heavy punitive damages, calling its conduct negligent and “despicable.”

The Inflation Reduction Act could put an end to blockbuster runs like that of Merck’s Keytruda. In the meantime, the drug keeps picking up more indications and positive clinical results.

Starting on Tuesday, U.S. Bankruptcy Judge Michael Kaplan in Trenton is due to hear several days of evidence and arguments before making a ruling.

The company and partner Seattle Children’s Therapeutics was studying its experimental therapy as a treatment for children with acute myeloid leukemia (AML), a cancer of the blood and bone marrow.

The 2023 American Society of Clinical Oncology (ASCO) meeting had implications for patients, physicians and biopharma companies.